The behavioral therapy-led platform now offers Microdose programs designed to support a personalized and sustainable weight loss journey
All products featured on Athletech News are independently selected by our editors. However, when you buy something through our retail links, we may earn an affiliate commission.
As more Americans are open to using GLP-1 meds, the real question is how service providers are going beyond prescriptions with ongoing support for lasting results.
Those who have struggled with their weight may already be familiar with Noom, which began as an online platform for behavioral therapy-driven nutrition and weight loss coaching. The company recently launched a new microdose option under Noom GLP-1Rx Program, which sets members up for success with a combination of physician-led care, personalized coaching and behavior change.
The Microdose GLP-1Rx Program starts at $99* per month for eligible users and includes compounded semaglutide or generic liraglutide alongside psychology-based nutrition, exercise and wellness coaching through the Noom app. The treatment uses smaller doses to ease users into GLP-1s and is designed to minimize reported side effects compared to its standard GLP-1Rx Program. Users can also add regular biomarker testing as part of the Proactive Health Microdose GLP-1 Rx Program to track and manage metabolic, hormonal and cardiovascular health.
What sets Noom apart from other telehealth services is its “gamified” platform that encourages users to meet their daily step and movement goals, make weekly commitments to check in, log their meals and read helpful tips from the app’s content library. All plan users can browse healthy recipes (including vegetarian-friendly, low-carb and dairy-free options) and get custom meal plans.
To keep people actively engaged, the app also features exclusive workout videos designed for GLP-1 users (such as moves for building or maintaining muscle), meditations for getting through stress and setbacks, support for managing side effects and access to community groups for motivation and connection.
The telehealth company’s latest findings support the idea that boosting engagement among GLP-1 users can help them adopt long-term health habits – and set themselves up for success long after they’ve taken their first shot or pill. Noom found that users who interact with the app the most lost about 25% more weight (or an extra 8.3 pounds) at 40 weeks, and remained on medication for more than twice as long as the least-engaged group1.
The new Microdose GLP-1Rx Program joins Noom’s standard Noom Med treatment that includes access to name-brand and compounded (generic) prescription medications for those users who clinically qualify. Telehealth for branded meds (such as Ozempic, Wegovy, Zepbound and Mounjaro) is also available.
Shedding pounds isn’t always a one-size-fits-all approach, and that’s where Noom stands out. Learn more and take the quiz to see if you qualify for Noom’s GLP-1Rx Programs here.
*Disclaimer: Noom GLP-1Rx Program involves healthy diet, exercise and support. Individual results vary. Meds & personalization based on clinical need. Not reviewed by FDA for safety, efficacy, or quality. No affiliation with Novo Nordisk Inc., the only US source of FDA-approved semaglutide. Not available in all 50 US states. Initial 3-week subscription and 4 weeks of medication from $99 plus tax and $199 per month plus tax for 12-week subscription thereafter. Final pricing depends on program selection.
- Data & methodology: These findings reflect observational analyses and report associations/correlations, not proof that engagement causes improved outcomes.
Weight loss: January 2026 analysis of 14,203 Noom GLP-1Rx Program members who started a GLP-1Rx plan and logged weight during a measurement week (4, 8, 16, 40 weeks). Engagement quartiles compare the frequency of Noom app opens (capped at 20 app opens per day) among users who weighed in within the specified measurement week..
Medication program persistence and engagement: January 2026 analysis of 30,239 Noom GLP-1Rx Program members who started a GLP-1Rx plan, evaluating program persistence by engagement quartile. Results based on users stratified into engagement quartiles during a trial period and then tracking the duration of their paid program membership. ↩︎
